{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:10Z","timestamp":1791375310719,"version":"4.3.1"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>In the phase 2, double\u2010blind, randomized controlled BEYOND trial (NCT03342404), luspatercept increased hemoglobin levels in patients with non\u2010transfusion\u2010dependent \u03b2\u2010thalassemia (NTDT). This study assessed long\u2010term effects of luspatercept on patient\u2010reported outcomes (PROs), using data from BEYOND and patients who continued luspatercept treatment in the phase 3b long\u2010term follow\u2010up (LTFU) study (NCT04064060). In BEYOND, patients received luspatercept or placebo Q3W for \u2265\u200948\u2009weeks. PRO instruments included NTDT\u2010PRO (BEYOND only), Functional Assessment of Chronic Illness Therapy\u2014Fatigue (FACIT\u2010F), and 36\u2010Item Short Form Survey (SF\u201036). Mixed\u2010effects models with repeated measures estimated least squares mean changes from baseline in PROs. PROs were evaluable in 144 patients (luspatercept 95, placebo 49) from BEYOND and 58 (luspatercept) from LTFU. Luspatercept improved NTDT\u2010PRO tiredness\/weakness and shortness of breath domain, FACIT\u2010F fatigue subscale, and SF\u201036 vitality scores versus placebo through double\u2010blind treatment (generally maintained through week 96). In LTFU patients, significant, meaningful improvements from baseline in FACIT\u2010F fatigue subscale and SF\u201036 vitality scores were observed within 12\u2009weeks of treatment initiation and maintained for up to 5\u2009years. Other FACIT\u2010F and SF\u201036 domains improved or were maintained throughout LTFU. Luspatercept offers rapid and durable benefits by improving anemia\u2010related symptoms and quality of life in patients with NTDT.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    Identifier: NCT03342404; NCT04064060\n                  <\/jats:p>","DOI":"10.1111\/ejh.70161","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:26:26Z","timestamp":1773980786000},"page":"161-173","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient\u2010Reported Outcomes With Luspatercept Through 5\u2009Years of Treatment in Patients With Non\u2010Transfusion\u2010Dependent \u03b2\u2010Thalassemia Treated in the\n                    <scp>BEYOND<\/scp>\n                    Trial"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-903X","authenticated-orcid":false,"given":"Khaled M.","family":"Musallam","sequence":"first","affiliation":[{"name":"Center for Research on Rare Blood Disorders (CR\u2010RBD) and Thalassemia &amp; Sickle Cell Center Burjeel Cancer Institute, Burjeel Medical City  Abu Dhabi UAE"},{"name":"Department of Public Health &amp; Epidemiology Khalifa University  Abu Dhabi UAE"},{"name":"Division of Hematology\/Oncology, Department of Pediatrics Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico SC Medicina ad Indirizzo Metabolico  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-0655","authenticated-orcid":false,"given":"Antonis","family":"Kattamis","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\u2010Oncology, First Department of Pediatrics National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dyer","sequence":"additional","affiliation":[{"name":"Formerly Bristol Myers Squibb  Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hnoosh","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7778-9890","authenticated-orcid":false,"given":"Laurie","family":"Eliason","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Pelligra","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shien","family":"Guo","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Mu","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loyse Felber","family":"Medlin","sequence":"additional","affiliation":[{"name":"Celgene International S\u00e0rl, a Bristol\u2010Myers Squibb Company  Boudry Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Reverte","sequence":"additional","affiliation":[{"name":"Celgene International S\u00e0rl, a Bristol\u2010Myers Squibb Company  Boudry Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H. M.","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali T.","family":"Taher","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2021838"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000806"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278684"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04370-2"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26428"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04456-5"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2015.05.011"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01623.x"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25584"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.15100"},{"key":"e_1_2_12_12_1","volume-title":"Guidelines for the Management of Non\u2010Transfusion\u2010Dependent \u03b2\u2010Thalassaemia","author":"Taher A. T.","year":"2023"},{"key":"e_1_2_12_13_1","unstructured":"Celgene Corporation REBLOZYL\u00ae(luspatercept\u2010aamt) for Injection for Subcutaneous Use. Prescribing Information 2024 https:\/\/packageinserts.bms.com\/pi\/pi_reblozyl.pdf."},{"key":"e_1_2_12_14_1","unstructured":"European Medicines Agency Reblozyl: Summary of Product Characteristics 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/reblozyl\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00208-3"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148535"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25344"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25343"},{"key":"e_1_2_12_19_1","unstructured":"FACIT Group Functional Assessment of Chronic Illness Therapy \u2013 Fatigue (FACIT\u2010F) Version 4 https:\/\/www.facit.org\/measures\/facit\u2010f."},{"key":"e_1_2_12_20_1","volume-title":"User's Manual for the SF\u201036v2 Health Survey","author":"Maruish M. E.","year":"2011"},{"issue":"3","key":"e_1_2_12_21_1","article-title":"Psychometric Evaluation of the NTDT\u2010PRO Questionnaire for Assessing Symptoms in Patients With Non\u2010Transfusion\u2010Dependent Beta\u2010Thalassaemia","volume":"13","author":"Taher A. T.","year":"2023","journal-title":"British Medical Journal Open"},{"issue":"11","key":"e_1_2_12_22_1","article-title":"Identifying Thresholds for Meaningful Improvements in NTDT\u2010PRO Scores to Support Conclusions About Treatment Benefit in Clinical Studies of Patients With Non\u2010Transfusion\u2010Dependent Beta\u2010Thalassaemia: Analysis of Pooled Data From a Phase 2, Double\u2010Blind, Placebo\u2010Controlled, Randomised Trial","volume":"14","author":"Taher A. T.","year":"2024","journal-title":"British Medical Journal Open"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-79"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0163278705275341"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10245"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70227"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016554"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70161","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70161","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:54:24Z","timestamp":1781873664000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/ejh.70161"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70161","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"2025-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}